MiNK Therapeutics, Inc.

Listed Company

INKTCIK 0001840229NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-12.49M

Total Assets

$14.24M

Equity

$-14.23M

Shares Out

4.98M

Op. Cash Flow

$-5.93M

INKT$10.74−54.30% · past yearDBEQ Basic

Daily closing prices

Business

MiNK Therapeutics is a biopharmaceutical company developing allogeneic, ex-vivo expanded invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its lead candidate agenT-797 is an off-the-shelf native iNKT cell therapy in Phase 2 trials across oncology, acute respiratory distress syndrome, and graft-versus-host disease. The company also advances engineered iNKT programs including CAR-iNKT candidates and bispecific engagers, leveraging proprietary manufacturing capabilities and access to immuno-oncology assets from a collaboration with Agenus.

Summary from 10-K filed 2026-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	6	6	15	23	14
General and administrative	7	4	7	8	5
Change in fair value of related party note	154,832	638,046	—	—	—
Operating loss	−13	−11	−23	−31	−28
Interest income, net	180,246	172,568	463,256	253,323	−2
Other income (expense), net	−32,000	331,000	−10	3	221,920
Net loss	−12	−11	−22	−28	−30
Basic net loss per common share	−2.93	−2.86	−6.54	−0.83	−1.16
Diluted net loss per common share	−2.93	−2.86	−6.54	−0.83	−1.16
Weighted average number of common shares outstanding, basic	4	4	3	34	26
Weighted average number of common shares outstanding, diluted	4	4	3	34	26
Foreign currency translation loss	−87,340	−200,629	−138,479	332,801	897,769
Comprehensive loss	−13	−11	−23	−28	−29

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	13	5	3	20	39
Prepaid expenses	276,431	246,600	53,111	298,667	1,761
Other current assets	211,202	164,244	177,964	470,300	744,321
Total current assets	14	5	4	20	40
Equipment, net of accumulated depreciation of $612,245 and $524,639 at December 31, 2025 and December 31, 2024, respectively	391,000	733,000	954,000	1	607,000
Total assets	14	6	5	21	40
Accounts payable	3	3	4	6	3
Accrued liabilities	2	2	5	4	2
Related party note	5	—	—	—	—
Other current liabilities	3	2	2	3	6
Total current liabilities	13	7	11	13	16
Related party note	—	5	—	—	—
Due to related parties	15	13	11	9	—
Commitments and contingencies	—	—	—	—	—
Common stock, par value $0.00001 per share, 150,000,000 shares authorized, 4,706,246 and 3,963,045 shares issued at December 31, 2025 and December 31, 2024, respectively	48	40	35	339	335
Additional paid-in capital	143	125	116	111	107
Accumulated other comprehensive loss	−718,916	−631,576	−430,947	−292,468	−625,269
Accumulated deficit	−157	−144	−133	−111	−83
Total stockholders' deficit	−14	−20	−18	−401,303	24
Total liabilities and stockholders' deficit	14	6	5	21	40

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−12	−11	−22	−28	−30
Depreciation	181,745	215,437	204,617	121,749	77,960
Share-based compensation	3	2	4	3	2
Loss on disposal of assets	169,800	—	—	—	—
Gain on deconsolidation	—	−185,351	—	—	—
Gain on forgiveness of liability	—	−2	−266,780	−3	—
Interest accrued on related party note	100,000	79,444	—	—	—
Prepaid expenses	−29,788	−194,173	245,589	−296,945	488,752
Accounts payable	689,710	−1	−2	3	−152,042
Accrued liabilities and other current liabilities	720,196	−393,771	2	3	—
Other operating assets and liabilities	2	2	3	3	3
Net cash used in operating activities	−6	−10	−16	−19	−13
Net proceeds from sale of equity	14	—	—	—	—
Proceeds from issuance of related party note	—	5	—	—	—
Proceeds from sale of shares in private placement	—	6	—	—	—
Purchase of treasury shares to satisfy tax withholdings	−173,353	—	−477,639	−157,194	—
Proceeds from employee stock purchases and option exercises	440,309	19,986	70,466	1,595	—
Net cash provided by financing activities	15	11	−407,173	−155,599	49
Effect of exchange rate changes on cash	−13,429	−54,699	−25,250	19,385	16,899
Net increase in cash and cash equivalents	9	1	−16	−19	36
Cash paid for interest	9,516	13,135	27,509	10,820	—
Issuance of stock options for payment of certain employee bonuses	—	1	—	—	—
Insurance financing agreement	257,164	172,000	109,000	444,000	643,000
Issuance of related party note (Note 10)	—	792,878	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is MiNK Therapeutics, Inc.'s CIK number?

MiNK Therapeutics, Inc.'s SEC CIK number is 0001840229 (1840229). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find MiNK Therapeutics, Inc.'s SEC filings?

All of MiNK Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did MiNK Therapeutics, Inc. last report earnings?

MiNK Therapeutics, Inc. (INKT) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-225369). This is MiNK Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is MiNK Therapeutics, Inc.'s most recent earnings 8-K?

MiNK Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001193125-26-225369. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View MiNK Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →